A review of the economics of treating Clostridium difficile infection

PharmacoEconomics

Volumn 32, Issue 7, 2014, Pages 639-650

  Mergenhagen, Kari A ^a   Wojciechowski, Amy L ^a   Paladino, Joseph A ^b,c  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c CPL Associates LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC ASSOCIATED DIARRHEA; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DRUG COST; FECES MICROFLORA; FOLLOW UP; GENETIC VARIABILITY; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; MICROBIOLOGY; MICROFLORA; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COST-BENEFIT ANALYSIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HEALTH CARE COSTS; HUMANS; MICROBIOTA; PROBIOTICS;

EID: 84903954933     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0161-y     Document Type: Review

References (100)

1. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S32-42. doi:10.1086/521860. (Pubitemid 351323663)
2. Frieden T. Antibiotic resistance threats in the United States. 2013. http://www.cdc.gov/drugresistance/threat-report-2013/, editor. CDC.gov2013.
3. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320(4):204-10. doi:10.1056/NEJM198901263200402. (Pubitemid 19034145)
4. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007;45(8):992-8. doi:10.1086/521854. (Pubitemid 47580347)
5. Gerding DN. Clostridium difficile 30 years on: what has, or has not, changed and why? Int J Antimicrob Agents. 2009;33(Suppl 1):S2-8. doi:10.1016/S0924-8579(09)70008-1.
6. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial- associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19-31. doi:10.1086/521859. (Pubitemid 351323662)
7. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433-41. doi:10.1056/NEJMoa051590. (Pubitemid 41770164)
8. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26(3):273-80. doi:10.1086/502539. (Pubitemid 40445086)
9. Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM 2nd, Killgore G, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38(5):640-5. doi:10.1086/381551. (Pubitemid 38333858)
10. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442-9. doi:10.1056/NEJMoa051639. (Pubitemid 41770165)
11. Johnson S, Samore MH, Farrow KA, Killgore GE, Tenover FC, Lyras D, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med. 1999;341(22):1645-51. doi:10.1056/NEJM199911253412203.
12. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173(9):1037-42. doi:10.1503/cmaj. 050978.
13. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079-84. doi:10.1016/S0140-6736(05)67420-X. (Pubitemid 41338761)
14. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40(11):1591-7. doi:10.1086/430315. (Pubitemid 40720808)
15. Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis. 2010;51(11):1306-13. doi:10.1086/657116.
16. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S43-9. doi:10.1086/521861. (Pubitemid 351323664)
17. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693-703. doi:10.1056/NEJMoa1012413.
18. Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O'Connor L, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med. 2013;369(13):1195-205. doi:10.1056/NEJMoa1216064.
19. Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6(2):105-8. doi:10.1016/j.jamda.2005.01.003. (Pubitemid 40353089)
20. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54(3):243-5. (Pubitemid 38002001)
21. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171(1):33-8. (Pubitemid 38925116)
22. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990;162(3): 678-84. (Pubitemid 20266159)
23. Dubberke ER, Reske KA, Olsen MA, McMullen KM, Mayfield JL, McDonald LC, et al. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C. difficile-associated disease. Arch Intern Med. 2007;167(10):1092-7. doi:10.1001/archinte.167.10.1092. (Pubitemid 46835798)
24. Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359-67. doi:10.1001/ jamainternmed.2013.7056.
25. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346-53. doi:10.1086/338260. (Pubitemid 34062235)
26. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46(4):497-504. doi:10.1086/526530. (Pubitemid 351263485)
27. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29(9):823-8. doi:10.1086/588756.
28. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28(11):1219-27. doi:10.1086/522676. (Pubitemid 47596558)
29. Paladino JA, Schentag JJ. The economics of Clostridium difficile-associated disease for providers and payers. Clin Infect Dis. 2008;46(4):505-6. doi:10.1086/526531. (Pubitemid 351263486)
30. Kuijper EJ, Coignard B, Tull P, difficile ESGfC, States EUM, European Centre for Disease P et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2-18. doi:10.1111/j.1469-0691.2006.01580.x. (Pubitemid 44362038)
31. Barbut F, Cornely O, Fitzpatrick F, Kuijper EJ, Nagy E, Rupnik M et al. Clostridium difficile infection in Europe: A CDI Europe Report; 2013.
32. Magalini S, Pepe G, Panunzi S, Spada PL, De Gaetano A, Gui D. An economic evaluation of Clostridium difficile infection management in an Italian hospital environment. Eur Rev Med Pharmacol Sci. 2012;16(15):2136-41.
33. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81(1):1-14. doi:10.1016/j.jhin.2012.02.004.
34. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88-92. doi:10.1093/cid/cis335.
35. McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect. 2012;18(3):282-9. doi:10.1111/j.1469-0691.2011.03571.x.
36. Shupo F, Dorey J, Aballea S, McGarry T, Odeyemi II, Toumi M. PIN75 health-related quality of life of Clostridium difficile infection: a methodological contribution to direct utility elicitation by TTO. Value Health. 2012;15(7):A399. doi:http://dx.doi.org/10.1016/j.jval.2012.08.1142.
37. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med. 1998;128(12 Pt 1):989-95. (Pubitemid 28275175)
38. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24(9):699-706. doi:10.1086/502278. (Pubitemid 37221343)
39. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect. 2009;73(4):305-15. doi:10.1016/j.jhin.2009. 04.019.
40. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-55. doi:10.1086/651706.
41. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478-98; quiz 99. doi:10.1038/ajg.2013.4.
42. Debast SB, Bauer MP, Kuijper EJ, on behalf of the Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1-26. doi:10.1111/1469-0691.12418.
43. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52(7):2403-6. doi:10.1128/AAC.00090-08. (Pubitemid 351915669)
44. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40(1):1-8. doi:10.1016/j.ijantimicag.2012.01.004.
45. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis. 2008;47(1):56-62. doi:10.1086/588293. (Pubitemid 351920588)
46. DuPont HL, Garey K, Caeiro JP, Jiang ZD. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Current Opin Infect Dis. 2008;21(5):500-7. doi:10.1097/QCO.0b013e32830f9397.
47. Al-Eidan FA, McElnay JC, Scott MG, Kearney MP, Corrigan J, McConnell JB. Use of a treatment protocol in the management of community-acquired lower respiratory tract infection. J Antimicrob Chemother. 2000;45(3):387-94. (Pubitemid 30139253)
48. Lahue BJ, Davidson DM. Metronidazole and vancomycin outcomes for Clostridium difficile-associated diarrhoea in a US hospital database. In: 17th European Congress of Clinical Microbiology and Infectious Diseases; Munich, Germany: European Society of Clinical Microbiology and Infectious Diseases; 2007.
49. Al-Eidan FA, McElnay JC, Scott MG, Kearney MP. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Phar Ther. 2000;25(2):101-9. (Pubitemid 30326409)
50. Thomas KL Holmes K, Jackson BR, Go M, Fang JC, Peterson KA. A cost comparison of metronidazole and vancomycin in the treatment of Clostridium difficile associated diarrhea [abstract]. Am J Gastroenterol. 2007;102(Suppl 2):S268.
51. Perras C, Tsakonas E, Ndegwa S, Conly J, Valiquette L, Farrah K. Vancomycin or metronidazole for treatment of Clostridium difficile infection: clinical and economic analyses. CADTH Health Technology Assessments. Ottawa (ON); 2011.
52. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet. 1983;2(8358):1043-6. (Pubitemid 14235361)
53. Butterworth SA, Koppert E, Clarke A, Wiggs B, MacFarlane JK. Recent trends in diagnosis and treatment of Clostridium difficile in a tertiary care facility. Am J Surg. 1998;175(5):403-7. doi:10.1016/S0002-9610(98)00058-0. (Pubitemid 28213455)
54. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302-7. doi:10.1086/519265. (Pubitemid 47101025)
55. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422-31. doi:10.1056/NEJMoa0910812.
56. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-9. doi:10.1016/S1473- 3099(11)70374-7.
57. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis. 2013;57(4):555-61. doi:10.1093/cid/cit346.
58. Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis. 2012;55(3):351-7. doi:10.1093/cid/cis430.
59. Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359-67. doi:10.1001/ jamainternmed.2013.7056.
60. Simon MS. Cost-effectiveness of fidaxomicin for Clostridium difficile treatment. Clin Infect Dis. 2014;58(4):603. doi:10.1093/cid/cit772.
61. Hartzema AG, Chen C. Is fidaxomicin worth the cost? The verdict is still out! Clin Infect Dis. 2014;58(4):604-5. doi:10.1093/cid/cit774.
62. Shah H, Doyle JJ, Belletti DA. An economic analysis: is fidaxomicin worth the cost? Clin Infect Dis. 2014;58(4):603-4. doi:10.1093/cid/cit773.
63. Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health. 2013;16(2):297-304. doi:10.1016/j.jval.2012.11.004.
64. Madkour N, Bounthavong M, Hsu DI. PGI21 a comparison of the cost-effectiveness of fidaxomicin, metronidazole, and vancomycin, in the treatment of Clostridium difficile-associated disease. Value Health. 2012;15(4):A138-9.
65. Alowayesh MS, Holdford D, Harpe SE. PIN35 decision analysis model evaluating the cost-effectiveness of fidaxomicin and vancomycin in the treatment of Clostridium difficile infection (CDI) from a hospital perspective. Value Health. 2012;15(4):A243.
66. RED BOOK Online® [database on the Internet]. Truven health analytics. http://www.micromedexsolutions.com. Accessed 30 Sept 2013.
67. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478-98; quiz 99. doi:10.1038/ajg.2013.4.
68. Guo B, Harstall C, Nguyen T, Ohinmaa A. Fecal transplantation for the treatment of Clostridium difficile-associated disease or ulcerative colitis. Institute of Health Economics. 2011; Alberta STE Report 1-60.
69. Faecal microbiota transplant for recurrent Clostridium difficile infection. NICE interventional procedure guidance 485. 2014. http://guidance.nice.org.uk/ipg485.
70. Louie T, Cannon K, O'grady H, Wu K, Ward L, editors. Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI). ID Week 2013; October 3, 2013; San Francisco, CA.
71. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38(6):475-83. (Pubitemid 38808419)
72. Rogers GB, Bruce KD. Challenges and opportunities for faecal microbiota transplantation therapy. Epidemiol Infect. 2013;141(11):2235-42. doi:10.1017/S0950268813001362.
73. Brandt LJ. American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol. 2013;108(2):177-85. doi:10.1038/ajg.2012.450.
74. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-15. doi:10.1056/NEJMoa1205037.
75. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994-1002. doi:10.1093/cid/cir632.
76. Mattila E, Uusitalo-Seppala R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142(3):490-6. doi:10.1053/j.gastro.2011.11.037.
77. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(7):1079-87. doi:10.1038/ajg.2012.60.
78. Avery L, Hasan M. Fecal bacteriotherapy for Clostridium difficile infections-its time has come. Clin Microbiol Newslett. 2013;35(15):119-24.
79. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36(5):580-5. doi:10.1086/367657. (Pubitemid 36259562)
80. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-9. doi:10.1016/j.cgh.2011.08.014.
81. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44(6):846-8. doi:10.1086/511870. (Pubitemid 46365312)
82. Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66(12):2850-5. doi:10.1093/jac/dkr377.
83. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37(1):122-8. doi:10.1111/apt.12111.
84. Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe. 2009;15(6):290-1. doi:10.1016/j.anaerobe.2009.08.004.
85. O'Connor JR, Galang MA, Sambol SP, Hecht DW, Vedantam G, Gerding DN, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008;52(8):2813-7. doi:10.1128/AAC. 00342-08.
86. Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol. 2011;49(12):4319-21. doi:10.1128/JCM.05100-11.
87. Curry SR, Marsh JW, Shutt KA, Muto CA, O'Leary MM, Saul MI, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis. 2009;48(4):425-9. doi:10.1086/596315.
88. Surawicz CM. Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2008;42(Suppl 2):S64-70. doi:10.1097/MCG.0b013e3181646d09.
89. Goldenberg JZ, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095. doi:10.1002/14651858.CD006095.pub3.
90. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;. doi:10.1016/S0140-6736(13)61218-0.
91. Belet N, Dalgic N, Oncel S, Ciftci E, Ince E, Guriz H, et al. Catheter-related fungemia caused by Saccharomyces cerevisiae in a newborn. Pediatr Infect Dis J. 2005;24(12):1125. (Pubitemid 43011080)
92. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256-64 quiz 446-447.
93. Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40(11):1625-34. doi:10.1086/429916. (Pubitemid 40720813)
94. Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002;35(10):1155-60. doi:10.1086/342912. (Pubitemid 35305862)
95. Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5(2):111-25. doi:10.1177/ 1756283X11428502.
96. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38(1):62-9. doi:10.1086/380455. (Pubitemid 38045874)
97. Curry SR, Schlackman JL, Hamilton TM, Henderson TK, Brown NT, Marsh JW, et al. Perirectal swab surveillance for Clostridium difficile by use of selective broth preamplification and real-time PCR detection of tcdB. J Clin Microbiol. 2011;49(11):3788-93. doi:10.1128/JCM.00679-11.
98. Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis. 2012;31(11):3163-71. doi:10.1007/s10096-012-1681-z.
99. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis. 1992;166(3):561-7.
100. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med. 1992;117(4):297-302.